Aragen Bioscience, Inc. Capacity Update April 2025: ADC

Join us for an in-depth exploration of Aragen’s comprehensive Antibody-Drug Conjugate (ADC) capabilities, structured into two key segments:

In Part 1, we will set the stage with a strategic overview of how ADCs have evolved into indispensable tools in modern therapeutics, followed by a deep dive into Aragen’s end-to-end solutions — ranging from state-of-the-art conjugation technologies and payload/linker chemistry to robust process optimization and manufacturing readiness. We will then showcase real-world success stories and critical lessons learned from our ADC journey, highlighting technical achievements and key milestones.

Building on this foundation, Part 2 offers a close look at Aragen’s specialized approach to toxin and linker development, emphasizing the manufacturing expertise that ensures both quality and safety. We will discuss best practices for toxin-linker conjugation — including scale-up considerations, regulatory compliance, and flexibility in handling complex, potent materials. Finally, the session will present how Aragen expertly manages each phase of an ADC project, ensuring seamless integration, compliance, and support throughout the entire development lifecycle.